Aging
Conditions
Keywords
Quercetin, Dasatinib, Epigenomics
Brief summary
Assessing the effects of Quercitin and Dasatinib over a 16 week period on participatns' epigenetic biological aging. The patients are being tested at baseline, halfway point, and after the trial period.
Detailed description
This is a prospective non-randomized clinical study of 20-25 patients to evaluate the effectiveness of Quercetin and Dasatinib supplements on the patient's epigenetic aging rate. The investigators predict that Quercetin and Dasatinib combined will slow cell proliferation and thus decelerate the rate of aging. There is evidence that Quercetin and Dasatinib slows cell proliferation and decelerates aging and the risk of age-related diseases. The aim of this pilot study is to evaluate the safety, efficacy and feasibility of Quercetin and Dasatinib as an effective treatment option to improve clinical care of healthy individual's epigenetic aging rate thus prolonging longevity. Despite considerable effort, successful treatment of reversing one's biological age has been shown to be a difficult therapeutic challenge. There is evidence that Dasatinib+Quercetin(Quercetin and Dasatinib) is a safe and effective treatment option to improve clinical care of healthy individual's biological age. Studies have shown that Dasatinib+Quercetin slows cell proliferation and decelerates aging and the risk of age-related diseases.
Interventions
Dasatinib plus Quercetin
Sponsors
TruDiagnostic
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
prospective non-randomized clinical study
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Men and women * Ages 40 and older * Patient must be able to comply with treatment plan and laboratory tests
Exclusion criteria
* Neoplastic cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision * No immune system issues or immunodeficiency disease * No history of viral illness which could be reactivated by immune down regulation * Presence of clinically significant acute or unstable cardiovascular and cerebrovascular (stroke) * Diagnosis of a transient ischemic attack in the 6 months prior to screening * Patients infected with hepatitis, C or HIV * Patients with Body Mass Index (BMI) \> 40 kg/m2 * Presence of active infection 9. Any other illness, psychiatric disorder, alcohol or chemical dependence that in the opinion of the investigator would render a patient unsuitable to participate in the study * Unable or unwilling to provide required blood sample for testing * As for the male-participants they are recommended to avoid fertilization for the first 6 months after the clinical trial. * If the patient has previously used Quercetin and Dasatinib.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Epigenetic Age Test | Change from baseline to 6 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Examining Methylation changes | Change from baseline to 6 months | Methylation analysis via the Illumina 850k epic array. Methylation will be assessed at 850,000 spots on the DNA, these are located on CpG sites. These are the spots on DNA that have cytosine and guanine right next to each other. |
Countries
United States
Outcome results
None listed